Cargando…
Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy. Thus, a therapeutic agent for the enterovirus-related disease is urgently needed. Remdesivir (GS-...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304253/ https://www.ncbi.nlm.nih.gov/pubmed/32595613 http://dx.doi.org/10.3389/fmicb.2020.01105 |
_version_ | 1783548229668831232 |
---|---|
author | Ye, Wei Yao, Min Dong, Yangchao Ye, Chuantao Wang, Dan Liu, He Ma, Hongwei Zhang, Hui Qi, Libin Yang, Yuewu Wang, Yuan Zhang, Liang Cheng, Linfeng Lv, Xin Xu, Zhikai Lei, Yingfeng Zhang, Fanglin |
author_facet | Ye, Wei Yao, Min Dong, Yangchao Ye, Chuantao Wang, Dan Liu, He Ma, Hongwei Zhang, Hui Qi, Libin Yang, Yuewu Wang, Yuan Zhang, Liang Cheng, Linfeng Lv, Xin Xu, Zhikai Lei, Yingfeng Zhang, Fanglin |
author_sort | Ye, Wei |
collection | PubMed |
description | Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy. Thus, a therapeutic agent for the enterovirus-related disease is urgently needed. Remdesivir (GS-5734) is a novel monophosphoramidate adenosine analog prodrug that exhibits potent antiviral activity against diverse RNA virus families, including positive-sense Coronaviridae and Flaviviridae and negative-sense Filoviridae, Paramyxoviridae, and Pneumoviridae. Currently, remdesivir is under phase 3 clinical development for disease COVID-19 treatment. Here, we found that remdesivir impeded both EV71 viral RNA (vRNA) and complementary (cRNA) synthesis, indicating that EV71 replication is inhibited by the triphosphate (TP) form of remdesivir. Moreover, remdesivir showed potent antiviral activity against diverse enteroviruses. These data extend the remdesivir antiviral activity to enteroviruses and indicate that remdesivir is a promising antiviral treatment for EV71 and other enterovirus infections. |
format | Online Article Text |
id | pubmed-7304253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73042532020-06-26 Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition Ye, Wei Yao, Min Dong, Yangchao Ye, Chuantao Wang, Dan Liu, He Ma, Hongwei Zhang, Hui Qi, Libin Yang, Yuewu Wang, Yuan Zhang, Liang Cheng, Linfeng Lv, Xin Xu, Zhikai Lei, Yingfeng Zhang, Fanglin Front Microbiol Microbiology Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy. Thus, a therapeutic agent for the enterovirus-related disease is urgently needed. Remdesivir (GS-5734) is a novel monophosphoramidate adenosine analog prodrug that exhibits potent antiviral activity against diverse RNA virus families, including positive-sense Coronaviridae and Flaviviridae and negative-sense Filoviridae, Paramyxoviridae, and Pneumoviridae. Currently, remdesivir is under phase 3 clinical development for disease COVID-19 treatment. Here, we found that remdesivir impeded both EV71 viral RNA (vRNA) and complementary (cRNA) synthesis, indicating that EV71 replication is inhibited by the triphosphate (TP) form of remdesivir. Moreover, remdesivir showed potent antiviral activity against diverse enteroviruses. These data extend the remdesivir antiviral activity to enteroviruses and indicate that remdesivir is a promising antiviral treatment for EV71 and other enterovirus infections. Frontiers Media S.A. 2020-06-12 /pmc/articles/PMC7304253/ /pubmed/32595613 http://dx.doi.org/10.3389/fmicb.2020.01105 Text en Copyright © 2020 Ye, Yao, Dong, Ye, Wang, Liu, Ma, Zhang, Qi, Yang, Wang, Zhang, Cheng, Lv, Xu, Lei and Zhang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Ye, Wei Yao, Min Dong, Yangchao Ye, Chuantao Wang, Dan Liu, He Ma, Hongwei Zhang, Hui Qi, Libin Yang, Yuewu Wang, Yuan Zhang, Liang Cheng, Linfeng Lv, Xin Xu, Zhikai Lei, Yingfeng Zhang, Fanglin Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition |
title | Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition |
title_full | Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition |
title_fullStr | Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition |
title_full_unstemmed | Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition |
title_short | Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition |
title_sort | remdesivir (gs-5734) impedes enterovirus replication through viral rna synthesis inhibition |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304253/ https://www.ncbi.nlm.nih.gov/pubmed/32595613 http://dx.doi.org/10.3389/fmicb.2020.01105 |
work_keys_str_mv | AT yewei remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT yaomin remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT dongyangchao remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT yechuantao remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT wangdan remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT liuhe remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT mahongwei remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT zhanghui remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT qilibin remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT yangyuewu remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT wangyuan remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT zhangliang remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT chenglinfeng remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT lvxin remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT xuzhikai remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT leiyingfeng remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition AT zhangfanglin remdesivirgs5734impedesenterovirusreplicationthroughviralrnasynthesisinhibition |